Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 10 of 10 entries
View as:

Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00734864 Org: User:
Start: 06/30/09 End: 06/30/12 Due: 06/30/13

Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG

Phase: N/A Priority: Normal
NCT ID: NCT00613132 Org: User:
Start: 05/31/05 End: 01/31/13 Due: 01/31/14

Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma

Phase: N/A Priority: Normal
NCT ID: NCT01989052 Org: User:
Start: 05/31/14 End: 02/29/16 Due: 02/28/17

Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT00613223 Org: User:
Start: 02/29/08 End: 05/31/11 Due: 05/31/12

Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)

Phase: N/A Priority: Normal
NCT ID: NCT00953121 Org: User:
Start: 09/30/09 End: 01/31/13 Due: 01/31/14

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT02540161 Org: User:
Start: 02/01/16 End: 04/27/20 Due: 04/27/21

Panitumumab and Irinotecan for Malignant Gliomas

Phase: N/A Priority: Normal
NCT ID: NCT01017653 Org: User:
Start: 02/28/10 End: 10/31/11 Due: 10/31/12

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00979173 Org: User:
Start: 11/30/09 End: 06/30/12 Due: 06/30/13

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

Phase: N/A Priority: Normal
NCT ID: NCT00613054 Org: User:
Start: 11/30/07 End: 04/30/09 Due: 04/30/10

Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure

Phase: N/A Priority: Normal
NCT ID: NCT01954030 Org: User:
Start: 10/31/13 End: 07/31/15 Due: 07/31/16